Ruiqi Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruiqi Chen has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Zhihong Li
Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, China
3 shared publications - Chao Tu
Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, China
2 shared publications - Lin Mei
Department of Orthopedics The Second Xiangya Hospital of Central South University Changsha Hunan China
2 shared publications Alexandra McCartney
Princess Margaret Cancer Centre Division of Medical Oncology and Hematology, Toronto, ON, Canada
1 shared publication- Amedra Basgaran
National Hospital for Neurology and Neurosurgery
1 shared publication - Binfeng Liu
Department of Orthopaedics The Second Xiangya Hospital of Central South University Changsha Hunan China
1 shared publication
Latest Publications
- Open Access
- 22 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (14) , e23783
SPP1 could be an immunological and prognostic biomarker: From pan‐cancer comprehensive analysis to osteosarcoma validation
Secreted phosphoprotein 1 (SPP1), also known as osteopontin, is a phosphorylated protein. High SPP1 expression levels have been detected in multiple cancers and are associated with poor prognosis and reduced survival rates. However, only a few pan‐cancer analyses have targeted SPP1. We conducted a comprehensive analysis using multiple public databases, including TIMER and TCGA, to investigate the expression levels of SPP1 in 33 different tumor types. In addition, we verified the effect of SPP1 on osteosarcoma. To assess the impact of SPP1 on patient outcomes, we employed univariate Cox regression and Kaplan–Meier survival analyses to analyze overall survival (OS), disease‐specific survival (DSS), and progression‐free interval (PFI) in these tumor patients. We also explored SPP1 gene alterations in various tumor tissues using cBioPortal. We then examined the relationship between SPP1 and clinical characteristics, TME, immune regulatory genes, immune checkpoints, TMB, and MSI using R language. In addition, we used GSEA to investigate the molecular mechanisms underlying the role of SPP1. Bioinformatics analysis indicated that SPP1 was upregulated in 17 tumors. Overexpression of SPP1 results in poor OS, DSS, and PFI in CESC, ESCA, GBM, LGG, LIHC, PAAD, PRAD, and skin cutaneous melanoma. SPP1 expression was positively associated with immunocyte infiltration, immune regulatory genes, immune checkpoints, TMB, MSI, and drug sensitivity in certain cancers. We found that high expression of SPP1 in osteosarcoma was related to drug resistance and metastasis and further demonstrated that SPP1 can stimulate osteosarcoma cell proliferation via CCND1 by activating the PI3K/Akt pathway. These findings strongly suggest that SPP1 is a potential prognostic marker and novel target for cancer immunotherapy.
- 22 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (14) , e23783
Open AccessSPP1 could be an immunological and prognostic biomarker: From pan‐cancer comprehensive analysis to osteosarcoma validation
Secreted phosphoprotein 1 (SPP1), also known as osteopontin, is a phosphorylated protein. High SPP1 expression levels have been detected in multiple cancers and are associated with poor prognosis and reduced survival rates. However, only a few pan‐cancer analyses have targeted SPP1. We conducted a comprehensive analysis using multiple public databases, including TIMER and TCGA, to investigate the expression levels of SPP1 in 33 different tumor types. In addition, we verified the effect of SPP1 on osteosarcoma. To assess the impact of SPP1 on patient outcomes, we employed univariate Cox regression and Kaplan–Meier survival analyses to analyze overall survival (OS), disease‐specific survival (DSS), and progression‐free interval (PFI) in these tumor patients. We also explored SPP1 gene alterations in various tumor tissues using cBioPortal. We then examined the relationship between SPP1 and clinical characteristics, TME, immune regulatory genes, immune checkpoints, TMB, and MSI using R language. In addition, we used GSEA to investigate the molecular mechanisms underlying the role of SPP1. Bioinformatics analysis indicated that SPP1 was upregulated in 17 tumors. Overexpression of SPP1 results in poor OS, DSS, and PFI in CESC, ESCA, GBM, LGG, LIHC, PAAD, PRAD, and skin cutaneous melanoma. SPP1 expression was positively associated with immunocyte infiltration, immune regulatory genes, immune checkpoints, TMB, MSI, and drug sensitivity in certain cancers. We found that high expression of SPP1 in osteosarcoma was related to drug resistance and metastasis and further demonstrated that SPP1 can stimulate osteosarcoma cell proliferation via CCND1 by activating the PI3K/Akt pathway. These findings strongly suggest that SPP1 is a potential prognostic marker and novel target for cancer immunotherapy.
- 4 October 2023
- Published by Springer Nature in Phenomics
- Vol. 4 (2) , 171-186
3D Models of Sarcomas: The Next-generation Tool for Personalized Medicine
Sarcoma is a complex and heterogeneous cancer that has been difficult to study in vitro. While two-dimensional (2D) cell cultures and mouse models have been the dominant research tools, three-dimensional (3D) culture systems such as organoids have emerged as promising alternatives. In this review, we discuss recent developments in sarcoma organoid culture, with a focus on their potential as tools for drug screening and biobanking. We also highlight the ways in which sarcoma organoids have been used to investigate the mechanisms of gene regulation, drug resistance, metastasis, and immune interactions. Sarcoma organoids have shown to retain characteristics of in vivo biology within an in vitro system, making them a more representative model for sarcoma research. Our review suggests that sarcoma organoids offer a potential path forward for translational research in this field and may provide a platform for developing personalized therapies for sarcoma patients.
- 4 October 2023
- Published by Springer Nature in Phenomics
- Vol. 4 (2) , 171-186
3D Models of Sarcomas: The Next-generation Tool for Personalized Medicine
Sarcoma is a complex and heterogeneous cancer that has been difficult to study in vitro. While two-dimensional (2D) cell cultures and mouse models have been the dominant research tools, three-dimensional (3D) culture systems such as organoids have emerged as promising alternatives. In this review, we discuss recent developments in sarcoma organoid culture, with a focus on their potential as tools for drug screening and biobanking. We also highlight the ways in which sarcoma organoids have been used to investigate the mechanisms of gene regulation, drug resistance, metastasis, and immune interactions. Sarcoma organoids have shown to retain characteristics of in vivo biology within an in vitro system, making them a more representative model for sarcoma research. Our review suggests that sarcoma organoids offer a potential path forward for translational research in this field and may provide a platform for developing personalized therapies for sarcoma patients.
- Open Access
- 18 August 2023
- Published by Elsevier in Data in Brief
- Vol. 50, 109500
Datasets for the effects of RUNX2 silencing on transcriptomic and metabolomic profiles in SJSA-1 osteosarcoma cells
- 18 August 2023
- Published by Elsevier in Data in Brief
- Vol. 50, 109500
Open AccessDatasets for the effects of RUNX2 silencing on transcriptomic and metabolomic profiles in SJSA-1 osteosarcoma cells
- 7 January 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 25 (42) , 4523-4535
The Emerging Role of Exosomal Non-coding RNAs in Musculoskeletal Diseases
: Exosomes are phospholipid bilayer-enclosed membrane vesicles derived and constitutively secreted by various metabolically active cells. They are capable of mediating hetero- and homotypic intercellular communication by transferring multiple cargos from donor cells to recipient cells. Nowadays, non-coding RNAs (ncRNAs) have emerged as novel potential biomarkers or disease-targeting agents in a variety of diseases. However, the lack of effective delivery systems may impair their clinical application. Recently, accumulating evidence demonstrated that ncRNAs could be efficiently delivered to recipient cells using exosomes as a carrier, and therefore can exert a critical role in musculoskeletal diseases including osteoarthritis, rheumatoid arthritis, osteoporosis, muscular dystrophies, osteosarcoma and other diseases. Herein, we present an extensive review of biogenesis, physiological relevance and clinical implication of exosome-derived ncRNAs in musculoskeletal diseases.
- 7 January 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 25 (42) , 4523-4535
The Emerging Role of Exosomal Non-coding RNAs in Musculoskeletal Diseases
: Exosomes are phospholipid bilayer-enclosed membrane vesicles derived and constitutively secreted by various metabolically active cells. They are capable of mediating hetero- and homotypic intercellular communication by transferring multiple cargos from donor cells to recipient cells. Nowadays, non-coding RNAs (ncRNAs) have emerged as novel potential biomarkers or disease-targeting agents in a variety of diseases. However, the lack of effective delivery systems may impair their clinical application. Recently, accumulating evidence demonstrated that ncRNAs could be efficiently delivered to recipient cells using exosomes as a carrier, and therefore can exert a critical role in musculoskeletal diseases including osteoarthritis, rheumatoid arthritis, osteoporosis, muscular dystrophies, osteosarcoma and other diseases. Herein, we present an extensive review of biogenesis, physiological relevance and clinical implication of exosome-derived ncRNAs in musculoskeletal diseases.
- Open Access
- 1 January 2020
- Published by F1000 Research Ltd in MedEdPublish
- Vol. 9 (1)
Who Wants to Translate? Evaluation of a Novel Medical Mandarin Education Program for and by Pre-Clerkship Medical Students
Purpose: Language discordance between patients and healthcare providers adversely affects health outcomes. Medical students at the University of Toronto (UofT) created a peer-led program for classmates with basic Mandarin skills to learn and practice medical Mandarin. This mixed method study explored participants’ perceptions of program delivery, motivations to participate, and resulting personal and professional development. Methods: Ten sessions with 25 unique participants were held over an academic year. Eight student-led sessions taught content paralleling pre-clerkship curriculum; two physician-led sessions promoted cultural understanding and practice tips. Focus groups and a post-program survey evaluated the program. Results: Two focus groups (n=12 participants) and 19 surveys (response rate=76%) were included. Students reported high program satisfaction and improved comfort speaking Mandarin in both casual and professional settings. Students’ motivations to participate in MMEP included witnessing language discordance, recognizing medical Mandarin as an asset, and community expectations. Outcomes included increased comfort with and likelihood of using clinical Mandarin in future patient care, a developing sense of peer linguistic and cultural community, and increased understanding of cultural diversity. Conclusions: These results provide a framework and lessons learned for students and faculty interested in developing similar language programs, thereby building capacity to bridge provision gaps in healthcare. Keywords: Undergraduate medical education; language; cultural competency; Medical Students; Chinese; Mandarin Keywords: Undergraduate medical education; language; cultural competency; Medical Students; Chinese; Mandarin
- 1 January 2020
- Published by F1000 Research Ltd in MedEdPublish
- Vol. 9 (1)
Open AccessWho Wants to Translate? Evaluation of a Novel Medical Mandarin Education Program for and by Pre-Clerkship Medical Students
Purpose: Language discordance between patients and healthcare providers adversely affects health outcomes. Medical students at the University of Toronto (UofT) created a peer-led program for classmates with basic Mandarin skills to learn and practice medical Mandarin. This mixed method study explored participants’ perceptions of program delivery, motivations to participate, and resulting personal and professional development. Methods: Ten sessions with 25 unique participants were held over an academic year. Eight student-led sessions taught content paralleling pre-clerkship curriculum; two physician-led sessions promoted cultural understanding and practice tips. Focus groups and a post-program survey evaluated the program. Results: Two focus groups (n=12 participants) and 19 surveys (response rate=76%) were included. Students reported high program satisfaction and improved comfort speaking Mandarin in both casual and professional settings. Students’ motivations to participate in MMEP included witnessing language discordance, recognizing medical Mandarin as an asset, and community expectations. Outcomes included increased comfort with and likelihood of using clinical Mandarin in future patient care, a developing sense of peer linguistic and cultural community, and increased understanding of cultural diversity. Conclusions: These results provide a framework and lessons learned for students and faculty interested in developing similar language programs, thereby building capacity to bridge provision gaps in healthcare. Keywords: Undergraduate medical education; language; cultural competency; Medical Students; Chinese; Mandarin Keywords: Undergraduate medical education; language; cultural competency; Medical Students; Chinese; Mandarin
- 1 November 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (31_suppl) , 141
Impact of depression and anxiety on cancer patients' perceptions of lifestyle behaviors.
141 Background: Health behaviors including tobacco use, alcohol consumption, and physical activity (PA) can impact outcomes in cancer survivors. While the peri-diagnostic period can be a "teachable moment" for behavior change, patients may face barriers including mental health comorbidities. We have previously identified that patient perceptions of behaviors can influence behavior change. Here, we evaluated the impact of anxiety and depression on patient perceptions of these behaviors. Methods: Cancer patients from all disease sites were surveyed (2016-17) on their smoking, alcohol habits, and PA, and perceptions of the impact of these behaviors on fatigue, survival, and quality of life (QofL). Survey data were linked with same day Edmonton Symptom Assessment Symptom (ESAS) anxiety and depression scores. Logistic regression models evaluated the impact of anxiety and depression on patient perceptions. Results: Of 496, 53% were male; median age, 60 years. At diagnosis, 20% were current smokers, 47% were current drinkers, and 67% were not meeting PA guidelines. 30% screened positive for anxiety (ESAS anxiety > 3) and 34% screened positive for depression (ESAS depression > 2); mean [standard deviation] scores were 1.9 [2.3] for anxiety and 1.5 [2.2] for depression. Most current smokers (> 80%) perceived smoking to negatively impact fatigue, survival and QofL. Smokers screening positive for anxiety were more likely to perceive smoking as harmful on survival (OR=9.09, 95% CI (1.15-100), P=0.04); greater ESAS anxiety scores were associated with perceiving smoking to worsen survival (OR=1.51 per point, 95% CI (1.04-2.17), P=0.03). While those less physically active at diagnosis (> 65%) felt that PA improves fatigue, survival and QofL and half of current drinkers (45%-50%) felt that alcohol worsens outcomes, anxiety and depression were not found associated with perceptions (P > 0.10). Conclusions: Among current smokers, greater anxiety scores and those screening positive for anxiety were more likely to perceive continued smoking as harmful to survival. Mental health comorbidities were not found to have an impact on patient perceptions of the effect of alcohol consumption and PA on fatigue, survival, and QofL.
- 1 November 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (31_suppl) , 141
Impact of depression and anxiety on cancer patients' perceptions of lifestyle behaviors.
141 Background: Health behaviors including tobacco use, alcohol consumption, and physical activity (PA) can impact outcomes in cancer survivors. While the peri-diagnostic period can be a "teachable moment" for behavior change, patients may face barriers including mental health comorbidities. We have previously identified that patient perceptions of behaviors can influence behavior change. Here, we evaluated the impact of anxiety and depression on patient perceptions of these behaviors. Methods: Cancer patients from all disease sites were surveyed (2016-17) on their smoking, alcohol habits, and PA, and perceptions of the impact of these behaviors on fatigue, survival, and quality of life (QofL). Survey data were linked with same day Edmonton Symptom Assessment Symptom (ESAS) anxiety and depression scores. Logistic regression models evaluated the impact of anxiety and depression on patient perceptions. Results: Of 496, 53% were male; median age, 60 years. At diagnosis, 20% were current smokers, 47% were current drinkers, and 67% were not meeting PA guidelines. 30% screened positive for anxiety (ESAS anxiety > 3) and 34% screened positive for depression (ESAS depression > 2); mean [standard deviation] scores were 1.9 [2.3] for anxiety and 1.5 [2.2] for depression. Most current smokers (> 80%) perceived smoking to negatively impact fatigue, survival and QofL. Smokers screening positive for anxiety were more likely to perceive smoking as harmful on survival (OR=9.09, 95% CI (1.15-100), P=0.04); greater ESAS anxiety scores were associated with perceiving smoking to worsen survival (OR=1.51 per point, 95% CI (1.04-2.17), P=0.03). While those less physically active at diagnosis (> 65%) felt that PA improves fatigue, survival and QofL and half of current drinkers (45%-50%) felt that alcohol worsens outcomes, anxiety and depression were not found associated with perceptions (P > 0.10). Conclusions: Among current smokers, greater anxiety scores and those screening positive for anxiety were more likely to perceive continued smoking as harmful to survival. Mental health comorbidities were not found to have an impact on patient perceptions of the effect of alcohol consumption and PA on fatigue, survival, and QofL.